BCL2 and acute myeloid leukemia: Venetoclax (VEN, ABT-199) is a BH3 mimetic that inhibits the anti-apoptotic effects of BCL-2 proteins, inducing cell death in AML blasts, and was approved by the FDA in 2018 for the treatment of older patients with AML who are not eligible for intensive chemotherapy [152].